Antitrust Enforcement In Health Care: A Risky And Evolving Landscape
Executive Summary
In the last 18 months, seven companies and four executives in the generic pharmaceuticals manufacturing sector were charged with antitrust violations, amassing penalties of over $426m. And this month, the Department of Justice Antitrust Division brought its first ever criminal charges for a conspiracy to lower wages to workers against the former owner of a physical therapist staffing company. With enforcement efforts ramping up – and COVID-19 adding additional scrutiny – health care companies will need a comprehensive antitrust compliance program to avoid enforcement actions.
You may also be interested in...
Making The Case For A Legislative Deal On Drug Pricing
Drawing on 24 years as a legislator and another 16 years as a leading lobbyist for biopharma, Jim Greenwood sees an opportunity for industry to put drug pricing ‘behind us’ with a legislative compromise.
NANS 2021: Nevro’s HF10 Spinal-Cord Stimulator Succeeds In Two Trials
SENZA PDN showed Nevro's HF10 spinal cord stimulation therapy provided sustained relief to patients with painful diabetic neuropathy. Results of a separate trial showed HF10 improved outcomes in patients with non-surgical refractory back pain.
Warning Letter Roundup & Recap – 19 January 2021
No device-related warning letters were released by the US FDA the week of 19 January.
Need a specific report? 1000+ reports available
Buy Reports